Lexicon Pharmaceuticals Inc
NASDAQ:LXRX

Watchlist Manager
Lexicon Pharmaceuticals Inc Logo
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Watchlist
Price: 0.7734 USD -1.45% Market Closed
Market Cap: 279.6m USD
Have any thoughts about
Lexicon Pharmaceuticals Inc?
Write Note

Gross Margin
Lexicon Pharmaceuticals Inc

93.5%
Current
67%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
93.5%
=
Gross Profit
4.9m
/
Revenue
5.2m

Gross Margin Across Competitors

Country US
Market Cap 279.6m USD
Gross Margin
94%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 314.6B USD
Gross Margin
67%
Country US
Market Cap 141.2B USD
Gross Margin
60%
Country US
Market Cap 117.3B USD
Gross Margin
78%
Country US
Market Cap 105.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 136.4B AUD
Gross Margin
52%
Country US
Market Cap 78.4B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
No Stocks Found

Lexicon Pharmaceuticals Inc
Glance View

Market Cap
279.6m USD
Industry
Biotechnology

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.

LXRX Intrinsic Value
0.5564 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
93.5%
=
Gross Profit
4.9m
/
Revenue
5.2m
What is the Gross Margin of Lexicon Pharmaceuticals Inc?

Based on Lexicon Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 93.5%.